#Medication Delivery Systems Market

[harshnews]

Medication Delivery Systems Market Size, Share, Key Drivers, Trends, Challenges and Competitive Analysis

"Global Medication Delivery Systems Market – Industry Trends and Forecast to 2028

Global Medication Delivery Systems Market, By Type (Oral Drug Delivery System, Injection- Based Drug Delivery System, Inhalation/ Pulmonary Drug Delivery System, Transdermal Drug Delivery System, Trans Mucosal Drug Delivery System, Carrier- Based Drug Delivery System, Other Types), Technology (Prodrug, Implants and Intrauterine Devices, Targeted Drug Delivery, Polymeric Drug Delivery, Other Technologies), Carrier Type (Liposomes, Nanoparticles, Microspheres, Monoclonal Antibodies, Others), Application (Cardiovascular Diseases, Oncology, Urology, Diabetes, CNS, Ophthalmology, Inflammatory Diseases Infections, Other Applications), End-Users (Hospitals, Specialized Clinics, Clinical Research & Development Centers), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) Industry Trends and Forecast to 2028

Access Full 350 Pages PDF Report @

The global Medication Delivery Systems Market is witnessing significant growth due to factors such as the increasing prevalence of chronic diseases, rising demand for self-administration devices, technological advancements in drug delivery systems, and the growing elderly population. The market is expected to showcase lucrative opportunities in the coming years, driven by the need for personalized and targeted drug delivery solutions, integration of digital health technologies, and the rising adoption of injectable biologics and biosimilars in healthcare practices. Moreover, the COVID-19 pandemic has further emphasized the importance of efficient medication delivery systems to ensure timely and accurate administration of therapies.

**Segments**

- By System Type: Prefilled syringes, autoinjectors, wearable injectors, injectable pens, infusion pumps, nasal sprays, nebulizers, and others. - By Application: Diabetes, oncology, autoimmune diseases, cardiovascular disorders, respiratory diseases, and others. - By End User: Hospitals & clinics, home care settings, ambulatory surgical centers, and others.

Considering the market players in the Medication Delivery Systems Market, several leading companies are actively participating in product innovation and strategic collaborations to strengthen their market position and cater to the evolving needs of healthcare providers and patients.

**Market Players**

- Becton, Dickinson and Company - Baxter International Inc. - Pfizer Inc. - Novartis AG - Gerresheimer AG - Johnson & Johnson Services, Inc. - GlaxoSmithKline plc - Novo Nordisk A/S - 3M - F. Hoffmann-La Roche Ltd

In conclusion, the Medication Delivery Systems Market is poised for substantial growth, fueled by the increasing demand for advanced drug delivery technologies, the rising burden of chronic diseases, and the shift towards patient-centric healthcare solutions. Market players are focusing on research and development initiatives to introduce innovative products and gain a competitive edge in the industry. With the integration of digital health solutions and emphasis on personalized medicine, the market is expectedThe Medication Delivery Systems market is experiencing remarkable growth, driven by various factors contributing to the expanding demand for efficient drug administration solutions. The surge in chronic diseases worldwide, coupled with the increasing elderly population, has necessitated the development of advanced medication delivery systems to ensure effective treatment outcomes. Moreover, the rising preference for self-administration devices and the advent of innovative technologies in drug delivery mechanisms have revolutionized the healthcare sector. The market is anticipated to witness significant opportunities in the foreseeable future, driven by the need for personalized drug delivery solutions and the integration of digital health technologies into medical practices.

Segmentation of the Medication Delivery Systems market based on system type includes prefilled syringes, autoinjectors, wearable injectors, injectable pens, infusion pumps, nasal sprays, nebulizers, among others. These diverse system types cater to a wide range of medical applications such as diabetes, oncology, autoimmune diseases, cardiovascular disorders, and respiratory conditions, among others. The market is also segmented by end-users, including hospitals & clinics, home care settings, and ambulatory surgical centers, reflecting the various settings where these medication delivery systems are utilized.

Key market players in the Medication Delivery Systems industry, such as Becton, Dickinson and Company, Pfizer Inc., Novartis AG, and Johnson & Johnson Services, Inc., are actively engaged in product innovations and strategic collaborations to enhance their market presence and meet the evolving needs of healthcare providers and patients. These companies are focusing on research and development efforts to introduce cutting-edge products that ensure efficient drug delivery and improve patient outcomes. The market landscape is characterized by intense competition, prompting companies to differentiate themselves through technological advancements and enhanced product offerings.

In conclusion, the Medication Delivery Systems market is set for substantial growth in the coming years, driven by the increasing demand for advanced drug delivery technologies and the escalating burden of chronic ailments globally. The industry's focus on patient-centric healthcare solutions, coupled with the integration of digital health solutions, is expected to propel market**Global Medication Delivery Systems Market**

- **Type:** Includes Oral Drug Delivery System, Injection-Based Drug Delivery System, Inhalation/Pulmonary Drug Delivery System, Transdermal Drug Delivery System, Transmucosal Drug Delivery System, Carrier-Based Drug Delivery System, and Other Types. - **Technology:** Encompasses Prodrug, Implants and Intrauterine Devices, Targeted Drug Delivery, Polymeric Drug Delivery, and Other Technologies. - **Carrier Type:** Comprises Liposomes, Nanoparticles, Microspheres, Monoclonal Antibodies, and Others. - **Application:** Targets Cardiovascular Diseases, Oncology, Urology, Diabetes, CNS, Ophthalmology, Inflammatory Diseases, Infections, and Other Applications. - **End-Users:** Includes Hospitals, Specialized Clinics, and Clinical Research & Development Centers.

The Global Medication Delivery Systems Market is witnessing robust growth and is poised for significant advancements in the forecast period. The proliferation of chronic diseases worldwide, coupled with the expanding elderly population, is fueling the demand for efficient drug delivery solutions. Technological innovations are revolutionizing the healthcare sector, with a focus on personalized and targeted drug delivery systems gaining traction. Integrating digital health technologies into medication delivery is a key trend shaping the market landscape, alongside the increasing adoption of injectable biologics and biosimilars in healthcare practices. The impact of the COVID-19 pandemic has underscored the critical need for precise and timely administration

Core Objective of Medication Delivery Systems Market:

Every firm in the Medication Delivery Systems Market has objectives but this market research report focus on the crucial objectives, so you can analysis about competition, future market, new products, and informative data that can raise your sales volume exponentially.

Size of the Medication Delivery Systems Market and growth rate factors.

Important changes in the future Medication Delivery Systems Market.

Top worldwide competitors of the Market.

Scope and product outlook of Medication Delivery Systems Market.

Developing regions with potential growth in the future.

Tough Challenges and risk faced in Market.

Global Medication Delivery Systems-top manufacturers profile and sales statistics.

Highlights of TOC:

Chapter 1: Market overview

Chapter 2: Global Medication Delivery Systems Market

Chapter 3: Regional analysis of the Global Medication Delivery Systems Market industry

Chapter 4: Medication Delivery Systems Market segmentation based on types and applications

Chapter 5: Revenue analysis based on types and applications

Chapter 6: Market share

Chapter 7: Competitive Landscape

Chapter 8: Drivers, Restraints, Challenges, and Opportunities

Chapter 9: Gross Margin and Price Analysis

How the Report Aids Your Business Discretion?

This section of this Market report highlights some of the most relevant factors and growth enablers that collectively ensure a high-end growth spurt

The report unravels details on pronounced share assessments across both country-wise as well as region-based segments

A leading synopsis of market share analysis of dynamic players inclusive of high-end industry veterans

New player entry analysis and their scope of new business models

The report includes strategic recommendations for new business veterans as well as established players seeking novel growth avenues

A detailed consultation services based on historical as well as current timelines to ensure feasible forecast predictions

A thorough evaluation and detailed study of various segments as well as sub-segments across regional and country-specific developments

Details on market estimations, market size, dimensions

A review of market competitors, their high-end product and service portfolios, dynamic trends, as well as technological advances that portray high end growth in this Market

Browse Trending Reports:

Asia Pacific Mainframe Market

Asia Pacific Menstrual Cramps Treatment Market

Europe Commercial Cleaning Equipment Market

Europe Mainframe Market

Europe Quantum Computing Market

Europe Tomatoes Market

Europe Utility Locator Market

India Blood Gas Analyzer Market

Middle East And Africa Commercial Cleaning Equipment Market

Middle East And Africa Neurosurgery Market

Middle East And Africa Sports Medicine Market

Middle East And Africa Vaccines Market

Nigeria Cassava Starch Market

Nigeria Starch Processing Market

North America Menstrual Cramps Treatment Market

North America Neurosurgery Market

West Africa Baby Food Market

Antenna Market

Baby Apparel Market

Cassava Starch Market

Castor Oil Market

Cenospheres Market

Coconut Water Market

Collagen Casings Market

Facility Management Market

Functional Confectionery Market

Hemp Seed Market

Infrared Imaging Market

Instant Noodles Market

Laundry Detergents Market

Menstrual Cramps Treatment Market

Micro And Nano Plc Market

Motorcycle Market

Neurosurgery Market

Nickel Alloy Market

Over The Counter Probiotic Supplements Market

Polycystic Kidney Disease Adpkd Market

Private Label Food And Beverage Market

Recreational Cannabis Market

Tofu And Tempeh Market

Tomatoes Market

Vaccines Market

Varnish Makers Market

Wireless Medical Device Connectivity Market

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us:

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC : +653 1251 975

Email: corporatesales@databridgemarketresearch.com"

[chemicalmarketwatch-sp]

Medical Polymer Market Outlook: Trends, Innovations, and Global Dynamics

The medical polymer market has become a pivotal sector, growing due to advancements in healthcare materials. Known for durability, flexibility, and biocompatibility, these polymers are essential across devices, surgical instruments, implants, packaging, and drug delivery systems. The rise in demand reflects industry trends, technological breakthroughs, and growing regulatory standards shaping this market.

The global medical polymer market is valued at USD 41.1 billion in 2024 and is projected to reach USD 60.5 billion by 2029, growing at 8.0% cagr from 2024 to 2029.

Key Market Trends

Biocompatibility Innovations: Biocompatible materials are essential in medical applications where patient safety is paramount. To meet this need, polycarbonate, polypropylene, and polyethylene polymers are engineered to strict medical standards, creating materials that offer safe, effective performance within the body.

Surge in Disposable Devices: Single-use medical products like gloves, syringes, and catheters are gaining traction, especially post-pandemic. Disposable polymers allow manufacturers to produce cost-effective, hygienic products, addressing modern healthcare’s need for cleanliness and infection control.

3D Printing Advancements: Customization has transformed through 3D printing, as tailored prosthetics and surgical tools become accessible. Polymers like PEEK are favored here for strength and adaptability, enabling precise medical solutions suited to individual patient needs.

Sustainability Drives: With heightened environmental awareness, medical manufacturers are focusing on bio-based and recyclable materials. This shift aims to reduce the ecological impact of medical products, reflecting the global push towards sustainable solutions.

Enhanced Drug Delivery Applications: Drug delivery systems require polymers that ensure controlled, sustained release of medication. Bioresorbable polymers are particularly beneficial here, facilitating targeted treatment in chronic and long-term therapies without additional interventions.

Growth Drivers in the Medical Polymer Market

Demand for Minimally Invasive Devices: Polymers are ideal for minimally invasive surgery tools due to their flexibility and durability. As demand for less invasive procedures grows, so does the need for these high-performing materials, making them integral to medical advancements.

Aging Population and Chronic Disease: The global increase in chronic health conditions and an aging population drive demand for medical-grade polymers in implants, devices, and products for ongoing care. This market growth reflects the need for durable, biocompatible materials to improve patient care.

R&D and Technological Investments: Innovations in polymer chemistry and healthcare applications expand the versatility of these materials. Significant R&D investment is pushing the boundaries, enabling entry into new applications and meeting stringent regulatory demands across regions.

Regional Market Insights

The market for medical polymers is expanding globally, with strong growth in North America, Europe, and Asia-Pacific. North America leads due to its advanced healthcare sector and robust R&D focus, while the Asia-Pacific region experiences rapid growth driven by healthcare expansion, population increases, and rising disposable incomes in emerging economies like China and India.

Emerging markets hold considerable growth potential, especially as they build their healthcare infrastructure and address increasing medical needs. Access to quality polymers helps these regions expand their healthcare capabilities, catering to larger populations with advancing healthcare needs.

Challenges and Future Prospects

The medical polymer market faces challenges, such as meeting rigorous regulatory requirements, managing high development costs, and addressing environmental concerns. Compliance with medical standards is necessary but can slow down product development and increase expenses. Additionally, the medical industry’s reliance on single-use polymers prompts a need for eco-friendly, recyclable solutions.

To know more Download PDF Brochure : 

The future remains promising. The market’s growth, driven by healthcare demands and technological advances, opens new opportunities in medical material innovation. Companies prioritizing sustainability, compliance, and R&D will be well-positioned to capitalize on the evolving needs of this essential industry.

As materials science and healthcare continue to intersect, medical polymers are set to play a critical role in advancing medical technologies, improving patient outcomes, and meeting global healthcare needs.

[pharmanucleus1]

Global Nasal drug Delivery Market, Forecast to 2030

Market Introduction 

The parenteral route, commonly referred to as the nasal drug delivery system, is an alternate method of medication administration. Drugs that can only be administered intravenously have been administered orally as an alternate method to allow for systemic availability. The benefits of this technology include simple administration, patient compliance, minimal dosage requirements, bypassing first pass metabolism, great penetration, quick absorption, and favourable outcomes. To administer the pharmaceuticals to treat the majority of CNS illnesses, such as Parkinson's disease and Alzheimer's disease, several drug delivery systems for nasal administration of liquid, semisolid, and solid formulation are being researched. 

Market Dynamics 

The market for nasal drug delivery technology is predicted to expand throughout the course of the forecast period as a result of factors such as rising chronic illness incidence, advanced technology, and rising demand for nasal drug delivery systems. Additionally, it is anticipated that increasing self-administration practises will present more growth opportunities for companies involved in the nasal drug delivery technology market. 

Click here for full report:

Market Scope 

The "Global Nasal Drug Delivery Technology Market Analysis to 2030" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of nasal drug delivery technology market with detailed market segmentation by systems, containers, dosage form, therapeutic application, end user and geography. The global nasal drug delivery technology market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading nasal drug delivery technology market players and offers key trends and opportunities in the market. 

Market Segmentation 

The global nasal drug delivery technology market is segmented on the basis of systems, containers, dosage form, therapeutic application and end user. Based on systems, the market is segmented as, unit dose, bi-dose and multi dose. On the basis of containers, the market is segmented into, pressurized containers and non-pressurized containers. Based on the dosage form, the nasal drug delivery technology market is classified as, nasal powders, nasal gels, nasal drops & liquids and nasal spray. On the basis of application, the global nasal drug delivery technology market is categorized as, allergic & non-allergic rhinitis, nasal congestion, vaccinations and other applications. Based on the end user, the global nasal drug delivery technology market is segmented into hospitals and home health care. 

Click here for full report:

Regional Analysis 

The research provides an in-depth analysis of the market including both qualitative and numerical data. It provides analysis and forecast of the global Nasal Drug Delivery Technologies market based on several market categories. Additionally, it provides market size and forecast estimation for the five major regions of North America, Europe, Asia Pacific (APAC), Middle East and Africa (MEA) and South & Central America for the years 2023 to 2030. The Nasal Medication Delivery Technology Market is further divided into related nations and sectors for each region. The research includes a worldwide analysis and extrapolation for 18 nations as well as information on current trends and opportunities in this area. 

The research examines factors influencing the market for nasal drug delivery technology from both the demand and supply sides. It also assesses market dynamics, such as drivers, constraints, opportunities, and future trends, that will have an impact on the market during the projected period. The study evaluates the political, economic, social, and technological aspects affecting the market for nasal drug delivery technology in each of the five regions, namely North America, Europe, APAC, MEA, and South & Central America. Following this evaluation, the report includes thorough PEST analyses for each of the five areas. 

[gatheringbones]

[“To understand the shortage of beds, it helps to think of just-in-time delivery. Companies like to have just enough space for what they need, work with, and sell, not more and not less. For a hospital, the human body is the object that is to be delivered, altered, and shipped away just in time. There should never be too many bodies, or too few bodies. There should be just the right number of bodies on just the right number of beds.

Good doctors, good nurses, and good assistants resist this logic all the time, but they are pushing a boulder up a mountain. Maintaining beds costs money. No hospital, in American commercial medicine, is going to maintain a reserve of beds when other hospitals do not do so. Since financial logic dominates medical logic, the country must always be unprepared for epidemics. There can never be a reserve of beds, nor for that matter a reserve of protective equipment or ventilators. Managers counting on a quarterly profit cannot factor in pandemics, which arrive about once a decade. Each time a plague comes, the situation will be defined as exceptional, and the shortages will make the emergency even worse than it had to be. Then money will fly around: not to where the doctors might want, since they will not be asked, but to the sectors of the economy with the loudest voices. This just happened, and with commercial medicine it will keep happening.

In the hospital, sad to say, a body is a widget. Kindly assistants, competent nurses, and decent physicians try to humanize the widget, but they are constrained by a system. A body creates revenue if the body is the right kind of sick for the right length of time. Certain kinds of illnesses, especially ones treatable (or reputed to be treatable) with surgery and drugs, make money. No one has an economic incentive to keep you healthy, to get you well, or for that matter to keep you alive. Health and life are human values, not financial ones; an unregulated market in the treatment of our bodies generates profitable sickness rather than human thriving.”]

timothy snyder, from our malady: lessons in liberty from a hospital diary, 2020

[dailyanarchistposts]

Author: Kevin Carson Topics: health care, left-libertarianism

Mutualist, at the livejournal blog of the same name, writes on “Building Consensus with Egalitarian Liberals in Healthcare Reform.”

His argument is that libertarians and egalitarian liberals are likely to disagree on demand-side issues like single-payer insurance vs. medical savings accounts, because they’re so closely tied up with differences in purchasing power. But liberals are more likely to be sympathetic to proposals to open up the supply of healthcare to competition. Breaking the power of the license cartels and the patent system, and eliminating barriers to a fully functioning market (i.e., permitting price competition through advertising) would drastically reduce the price of healthcare and greatly empower the consumer.

And, I’d add, if we did that, discussion of demand-side reforms might be a lot more politically feasible.

Liberal welfare-statism is a pretty natural--if misguided--reaction to a society in which the state, through privilege, creates great disparities in income. Privilege creates massive distortions, made cumulative through the process of feedback, that must be dealt with somehow. One way of dealing with the consequences is through a Rube Goldberg device like redistributive welfare policy, another layer of policy to counteract the first layer, to prevent underconsumption from becoming too destabilizing and the underclass from becoming too radicalized. The other way is to eliminate the privilege itself--a lot simpler.

But make no mistake. If the privilege remains, statist “corrective” action will be the inevitable result. That’s why I don’t get too bent out of shape about the statism of the minimum wage or overtime laws--in my list of statist evils, the guys who are breaking legs rank considerably higher than the ones handing out government crutches. All too many libertarians could care less about the statism that causes the problems of income disparity, but go ballistic over the statism intended to alleviate it. It’s another example of the general rule that statism that helps the rich is kinda sorta bad, maybe, I guess, but statism that helps the poor is flaming red ruin on wheels.

Libertarians need to stop admiring the emperor’s clothes and pretending that disparities in income reflect the triumph of industrious ants over lazy grasshoppers. Liberals might be a lot easier to talk to then. That Galt’s Gulch bullshit can be kind of hard to listen to sometimes.

I’ve argued elsewhere myself, by the way, that we need to go beyond cooperative solutions to healthcare finance, and get into cooperatively organizing delivery of service, as well.

[eretzyisrael]

A novel radiation treatment for cancer with a 100-percent success rate in its pilot trial is now in Phase 3 pivotal trials ahead of receiving Food and Drug Administration (FDA) approval.

Jerusalem-based startup Alpha TAU is expanding its trials of the treatment for skin and other cancer, after its first trial of 10 patients succeeded beyond the company’s expectations.

“Those patients got 100 percent CR [complete response],” Sofer says.  

The pilot trial, conducted at multiple locations in the US last year, examined whether Alpha TAU’s DaRT (Diffusing Alpha-emitters Radiation Therapy) technology could successfully deliver targeted radiation therapy to patients with malignant skin and superficial soft tissue tumors that had returned or could not be removed surgically. 

Alpha TAU had hoped that the treatment would be successful in at least seven of the 10 trial participants, but instead registered successful delivery to all 10. CT scans showed a 100 percent complete response rate at 12 weeks after the treatment and again at 24 weeks, with no evidence of the disease recurring in any of the subjects. 

The results showed only mild or moderate side effects related to the device, and no systemic toxicity from it. 

Radiation therapy for cancer normally uses beta and gamma particles. Alpha particles, while proving deadly for cancer cells in a tumor, are not traditionally used as they cannot travel far in solid masses. 

Alpha DaRT, however, delivers the alpha particles directly into the tumor via a narrow device, inserted under local anesthetic, for a period of two to three weeks. The device is then removed and the patient monitored. 

The findings of the pilot trial were published this month in the Journal of the American Medical Association (JAMA), months after submitting the results to the FDA. 

The treatment is now undergoing its pivotal trial – the final one before the American agency gives it approval.  

“We submitted the results that you see now to the FDA, and the FDA told us that we can submit the protocol for the last phase, the pivotal,” says Sofer. 

A pivotal trial is required by the US and European Union drug agencies in order to receive approval to market a new form of medication; studies can involve thousands of subjects and test the efficacy and impact of a drug. 

Sofer says that the successful findings of the trial has led to medical institutes around the world clamoring to work with Alpha TAU, but for now research is limited to just a handful of locations for the pivotal trial. 

“Many, many, many centers all around the world want to participate,” he says. “We are working with 20 centers in the US, two or three centers in Canada and another four in Israel that are going to participate in this trial.”  

Sofer says Alpha TAU will be ready to submit the findings of the pivotal trial in around a year and a half from now. 

“We will have six months of follow up, then we will analyze the results and send it to the FDA,” he says of the current trial. “The submission to the FDA can be in about 18 months from now.” 

The revolutionary treatment is also being tried on other cancers, according to Sofer, who clarifies that, “right now it’s only for solid tumors.”

“We’re working on pancreas and lung and breast [cancer],” he says, explaining that the company is currently at various stages of testing for these other forms of malignant tumors. 

The device itself is easy to use and does not require specialized and often costly equipment in order to treat patients.  

“When it is approved, it will be for any hospital, medical cancer center, all over the world,” Sofer explains. 

“You don’t need any special equipment, and you don’t need the shielding,” he says, referring to the protective gear used in other forms of radiation therapy but are not needed for alpha particles. 

“It will be very simple to implement. You don’t need special equipment or investment in capital expenditure or something like that, [just] regular tools.” 

[everfastfrieght]

Air Freight Forwarder in India: Seamless Logistics with Everfast Freight

In today's fast-paced global economy, air freight has become an indispensable solution for businesses looking to transport goods quickly and efficiently across borders. India, as a hub of international trade, witnesses significant demand for reliable air freight services. Everfast Freight, a leader in logistics, provides exceptional air freight forwarding services tailored to meet diverse business needs.

Why Choose Air Freight for Your Business? Air freight is the fastest mode of transporting goods internationally. Businesses opt for air freight to ensure:

Quick delivery: Ideal for time-sensitive shipments like medical supplies, high-value goods, or seasonal products. Global connectivity: Access to virtually any destination in the world. Reduced risk: Minimized chances of theft or damage due to shorter transit times. However, the success of air freight heavily depends on the expertise of the freight forwarder managing the process.

Everfast Freight: Your Trusted Air Freight Partner As a premier air freight forwarder in India, Everfast Freight stands out with its customer-centric approach and unmatched expertise. Here's why businesses rely on Everfast Freight:

Comprehensive Global Network Everfast Freight boasts a robust network of international partners, ensuring seamless delivery to any part of the world. From Europe to the Americas, Africa to Asia, your shipments are handled with precision and care.

Customized Solutions Every shipment is unique, and Everfast Freight understands this. They offer tailored solutions to accommodate the size, weight, and urgency of your cargo, ensuring cost-effectiveness without compromising on quality.

Transparent Pricing Hidden costs can disrupt a business's budget. Everfast Freight provides clear and transparent pricing, helping clients plan their logistics effectively.

Cutting-Edge Technology With advanced tracking systems, Everfast Freight enables clients to monitor their shipments in real time, providing peace of mind and transparency.

Experienced Team The company’s skilled professionals have in-depth knowledge of customs regulations, documentation, and compliance requirements, ensuring smooth clearance and on-time delivery.

Industries Benefiting from Everfast Freight's Air Freight Services Everfast Freight caters to a wide range of industries, including:

E-commerce: Rapid delivery of products to global customers. Pharmaceuticals: Safe and timely transportation of temperature-sensitive goods. Automotive: Swift delivery of parts to meet manufacturing deadlines. Fashion: Quick distribution of seasonal collections to international markets. How Everfast Freight Ensures Sustainability In addition to speed and reliability, Everfast Freight prioritizes sustainability in its air freight operations. By optimizing routes and consolidating shipments, the company reduces its carbon footprint while maintaining efficiency.

Partner with Everfast Freight Today Whether you're shipping lightweight parcels or bulky cargo, Everfast Freight ensures a hassle-free air freight experience. With their dedication to excellence, they help businesses in India stay competitive in the global market.

Contact Everfast Freight today to learn how their air freight forwarding services can transform your logistics strategy.

[nerdybeardcollective]

Investment Surge in GLP-1 Drugs Market: Trends and Future Prospects

Market Growth and Investment Trends

The GLP-1 drugs market has seen substantial investment from pharmaceutical companies and venture capitalists. This is driven by the increasing prevalence of type 2 diabetes and obesity, coupled with the efficacy of GLP-1 drugs in managing these conditions. Key trends include:

Rising Prevalence of Diabetes and Obesity: The global rise in lifestyle-related health issues is fueling demand for effective treatments.

Innovative Drug Development: Companies are investing heavily in R&D to develop next-generation GLP-1 drugs with improved efficacy and fewer side effects.

Strategic Collaborations and Partnerships: Collaborations between pharmaceutical giants and biotech firms are accelerating innovation and market entry of new drugs.

Recent Developments

Several notable developments have occurred in the GLP-1 drugs market:

New Drug Approvals: Regulatory bodies like the FDA and EMA have recently approved several new GLP-1 receptor agonists, expanding treatment options.

Clinical Trials and Research: Ongoing clinical trials are investigating the broader therapeutic potential of GLP-1 drugs, including their effects on cardiovascular health and non-alcoholic fatty liver disease (NAFLD).

Technological Advancements: Innovations in drug delivery systems, such as oral formulations and long-acting injectables, are enhancing patient compliance and convenience.

Browse Press Release

Future Opportunities

The future of the GLP-1 drugs market holds numerous opportunities for growth and innovation:

Expansion into New Therapeutic Areas: Research suggests potential applications of GLP-1 drugs in conditions beyond diabetes and obesity, such as neurodegenerative diseases and inflammation.

Personalized Medicine: Advances in genomics and biomarkers may enable personalized GLP-1 therapies tailored to individual patient profiles, improving outcomes.

Emerging Markets: Increasing healthcare access and rising diabetes prevalence in emerging markets present significant growth opportunities for GLP-1 drugs.

Conclusion

The GLP-1 drugs market is poised for remarkable growth, driven by robust investment, innovative developments, and expanding therapeutic applications. As research progresses and new technologies emerge, GLP-1 receptor agonists will play a crucial role in addressing the global burden of diabetes, obesity, and potentially other diseases, offering improved health outcomes for millions.

About iDataAcumen

iDataAcumen is a global business intelligence and management consulting firm providing data driven solutions to a wide array of business challenges. Our clients are present across major geographies globally and belong to industries ranging mainly from healthcare, pharmaceuticals, life science, biotechnology, medical devices, food industry, chemicals, among others. We have catered to more than 500 clients across these industries.

We aspire to help our clients build a sustainable business by providing them robust business insights that are derived from sound data driven analysis. In today’s ever changing business environment, its become important to look objectively at your own business just as it is important to look at the competition. Technological advancement including but not limited to big data, artificial intelligence, and machine learning are helping industries worldwide to make informed business decisions. Our research process also makes use of some of these advanced tools to uncover valuable insights from vast amount of data to arrive at logical conclusions.

[newstfionline]

Friday, May 10, 2024

Biden Says the U.S. Will Not Supply Israel With Weapons to Attack Rafah (NYT) President Biden acknowledged on Wednesday that American bombs have been used to kill Palestinian civilians as he warned that the United States would withhold certain weapons if Israel launches a long-threatened assault in southern Gaza. In some of his strongest language to date on the seven-month war, Mr. Biden said the United States would still ensure Israel’s security, including the Iron Dome missile defense system and Israel’s “ability to respond to attacks” like the one Iran launched in April. But he said he would block the delivery of weapons that could be fired into densely populated areas of Rafah, where more than a million Palestinians are sheltering. The president had already halted the shipment of 3,500 bombs last week out of concern that they might be used in a major assault on Rafah—the first time since Hamas attacked Israel on Oct. 7 that Mr. Biden has leveraged U.S. arms to try to influence how the war is waged. On Wednesday, he said that he would also block the delivery of artillery shells.

With inflation soaring, Argentina will start printing 10,000 peso notes (AP) Prices in Argentina have surged so dramatically in recent months that the government has multiplied the size of its biggest bank note in circulation by five—to 10,000 pesos, worth about $10. The central bank announcement Tuesday promised to lighten the load for many Argentines who must carry around giant bags—occasionally, suitcases—stuffed with cash for simple transactions. Argentina’s annual inflation rate reached 287% in March, among the highest in the world. The new denomination note—five times the value of the previous biggest bill—is expected to hit the streets next month in a bid to “facilitate transactions between users,” the central bank said. The 10,000 peso note is worth $11 at the country’s official exchange rate and $9 at the black market exchange rate.

A grand Olympic plan. But first, the tent camps have to go. (Washington Post) He’d been living in the tent for nine days when the police arrived. “Bonjour, monsieur!” an officer shouted. “Reveille!” Ba Dak crawled out of his sleeping bag, unzipped the tent flap and stepped into the frigid February air. The camp, tucked beneath the Charles de Gaulle Bridge on the northern bank of the Seine River, bustled with movement in the windy pre-dawn darkness. Police officers in neon green vests marched between rows of tents, whose inhabitants rose from slumber to pack their belongings. The government was seeking to remove unhoused people from its streets before the Olympic Games shines a global spotlight on Paris this summer. Officials billed it as an innovative effort to ease Paris’s housing crisis, by relocating people to newly constructed facilities around the country rather than hotels in the city’s emergency shelter system. But advocates for refugees claim the government had more specific motives: to clear Paris of its tent villages, free up thousands of hotel rooms before the Games and identify people who aren’t eligible to legally remain in the country.

The mothers and wives of missing Russian servicemen have become some of the war effort’s biggest critics. (WSJ) Tens of thousands of relatives and friends use social media to swap information in the hopes of learning their loved ones’ fates. Under Russian law, soldiers aren’t declared dead without a recovered body, a death certificate from a medical examiner or a court ruling. In Ukraine, many troops are unaccounted for including deserters and prisoners of war. The Kremlin hasn’t released the number of MIAs. Russian antiwar commentators accuse the military of abandoning dead fighters to avoid compensating their families. President Vladimir Putin ordered them to get the equivalent of $54,600, plus the previously set compensation of around $26,000. Russian officials didn’t respond to a request for comment.

Ukrainians are using the cover of war to escape taxes (Economist) Since Russia invaded in 2022, Ukraine’s economy has shrunk by a quarter. But the ravages of war are not the only reason for the government’s reduced tax take. Businesses are also making use of the chaos to dodge paying their fair share. This is particularly true in agriculture, which before the war was responsible for 40% or so of Ukraine’s exports by income. The sector has been transformed by a scramble to find export routes safe from Russian attack. As Taras Kachka, Ukraine’s deputy minister for agriculture, notes, this disturbance has provided plenty of opportunity for farmers to “optimise taxes”. Around 6.5m Ukrainians—or 15% of the country’s pre-war population—have left the country, shrinking the domestic food market. At the same time, Russia is targeting transport infrastructure, grain silos and other agricultural equipment, which has driven up costs. Many workers have been recruited by the armed forces, and are at the front. Farmers therefore not only have new opportunities to dodge taxes, they are also increasingly desperate. The result is that two of every five tonnes of grain harvests now avoid contributing to state coffers, according to Mr Kachka’s estimates.

Myanmar: A hidden war (NYT) A people take to arms and fight for democracy. A military terrorizes civilians with airstrikes and land mines. Tens of thousands are killed. Millions are displaced. Yet it is all happening almost completely out of view in the Southeast Asian nation of Myanmar. Now, for the first time, the rebels claim control of more than half of Myanmar’s territory. In recent weeks they have overrun dozens of towns and Myanmar military bases. Even without foreign intervention, or much Western aid at all, the Myanmar resistance has pushed back the junta. Rebels are now within 150 miles of the capital, Naypyidaw. But that may have been the easy part. The resistance is—perhaps hopelessly—splintered. More than a dozen major armed ethnic groups are vying for control over land and valuable natural resources. Much of Myanmar is fractured between different groups, all heavily armed. Crime is flourishing. The country is now the world’s biggest producer of opium. Jungle factories churn out meth and other synthetic drugs that have found their way to Australia. Myanmar’s civil war may be overshadowed by other global conflicts. But to the Burmese who live with uncertainty and chaos, the war has never been more urgent or real.

In rapidly ageing China, millions of migrant workers can’t afford to retire (Reuters) After three decades selling homemade buns on the streets of the Chinese city of Xian, 67-year-old Hu Dexi would have liked to slow down. Instead, Hu and his older wife have moved to the edge of Beijing, where they wake at 4 a.m. every day to cook their packed lunch, then commute for more than an hour to a downtown shopping mall, where they each earn 4,000 yuan ($552) monthly, working 13-hour shifts as cleaners. The alternative for them and many of the 100 million rural migrants reaching retirement age in China over the next 10 years is to return to their village and live off a small farm and monthly pensions of 123 yuan ($17). The generation that flocked to China’s cities at the end of last century, building the infrastructure and manning the factories that made the country the world’s biggest exporter, now risks a sharp late-life drop in living standards.

Rafah and humanitarian aid (Washington Post) By Tuesday, Israeli forces had seized the pivotal Rafah border crossing that links Gaza to Egypt’s Sinai peninsula. Israel intensified bombardments on parts of the city, hitting houses and residential towers, and prompted more than 100,000 people into a panicked evacuation. The Rafah border crossing was closed, though Israeli authorities said another crossing at Kerem Shalom remained open to funnel critical supplies into Gaza—a claim questioned by aid groups. “The crossing area has ongoing military operations and is an active war zone,” Louise Wateridge, a spokeswoman for UNRWA, the U.N.’s agency for Palestinians, currently in Rafah, said Wednesday. “We are hearing continued bombardments in this area throughout the day. No fuel or aid has entered into the Gaza Strip, and this is disastrous for the humanitarian response.” “All the fuel that entered Gaza went through Rafah crossing,” said Jeremy Konyndyk, president of Refugees International, at a joint news briefing Wednesday of prominent humanitarian organizations. “The whole aid operation runs on fuel, so if the fuel is cut off, the humanitarian operation collapses. Water can’t be pumped. Lights cannot be kept on in hospitals. Vehicles cannot distribute aid.”

“Annihilation Prevention”—Why Some Gaza Families Choose To Split Up (Zumadaraj/English edition) Umm Raja Barbakh, a Gazan woman in her 60s, had a particular request to her children and grandchildren amid Israel’s relentless bombing campaign: when we flee, let’s choose different destinations. The reason is as simple as it is grim: She doesn’t want all her progeny in the same place for fear that the whole family could be annihilated. “The decision to disperse my children and grandchildren is a way to limit the chance that the whole family is gone in case of a bombing on a single place,” she explained. “Their presence in more than one place will reduce the risk of the family disappearing completely.” Indeed, that’s what happened with her sister, who was killed in an Israeli bombing along with her children and grandchildren. Barbakh’s family has instead scattered in different locations in the cities of Khan Younis and Rafah in southern Gaza. The oldest of her four children has sheltered in a tent in the Mawasi area in Rafah along with his seven children. A second son and daughter were living with their children in different locations in Rafah. The fourth lives with his five children in Khan Younis.

Smile! (Les Echos/France) It’s amazing to think that this slight movement of the lips and facial muscles, which sometimes lights up an entire face, can resonate so deeply within us and awaken a whole range of emotions—even if it comes from a complete stranger. Neuroscience has established that smiling feels good, and it starts very early. Fetal ultrasound scans have shown that, from the 26th week, babies smile to express a form of satisfaction, particularly after their mother has eaten a certain type of food. We now know that smiling stimulates the areas of the brain associated with reward circuits. And that it lowers levels of cortisol, the stress hormone. It slows the heart rate and lowers blood pressure. Two recent studies have even shown that this beneficial effect holds true even when we smile mechanically, though more modestly—it’s as if the simple act of mobilizing one of the 15 muscles involved in smiling sends a positive signal to the brain.       Another older study from Wayne State University suggests that smiling increases life expectancy. It was based on photographs of 230 American baseball league players taken in 1952. The sportsmen who did not smile in the photographs died at an average age of 72.9. Those who had big smiles lived to 79.9. Smiles also open doors. Traveler Charly Guérin has had many opportunities to verify this. He met a Bolivian grandmother in Sucre on her front doorstep who, simply on the strength of an impromptu smile, invited him into her home, where he ended up spending the afternoon chatting. “If you take the time to meet someone, a smile is a real open sesame,” the globetrotter says. On his blog, he also tells the story of Sarah, a French woman who set off around the world on a shoestring budget and who, when she wanted to attend a concert or sporting event, didn’t hesitate to stand in front of the entrance to the venue with a sign: “Exchange a free ticket for a smile.” And incredible as it may seem, it worked on many occasions.

[news-views-updates]

Healthcare IT Integration Market Size Expected to Reach USD 11.16 Billion by 2030

The global Healthcare IT Integration market size, which was valued at USD 4.38 billion in 2022, is anticipated to witness remarkable growth, reaching USD 11.16 billion by 2030. This projection reflects a robust Compound Annual Growth Rate (CAGR) of 12.4% over the forecast period spanning from 2023 to 2030.

The increasing demand for efficient healthcare delivery systems, coupled with the rising adoption of electronic health records (EHRs) and other digital solutions, is driving the growth of the Healthcare IT Integration market. Healthcare organizations worldwide are realizing the significance of integrating disparate systems and applications to streamline workflows, improve patient care, and enhance operational efficiency.

Key Market Segments:

The Healthcare IT Integration market is segmented by Products & Services type, End User, and Regions:

Products & Services Type:

Products: Interface Engines, Media Integration Software, Medical Device Integration Software, Other Integration Tools

Services: Support and Maintenance Services, Implementation and Integration Services (Training and Education Services, Consulting Services)

End User:

Hospitals

Clinics

Diagnostic Imaging Centers

Laboratories

Other End Users

Regions: The global market forecast covers various regions across the globe.

Market Outlook:

The increasing adoption of electronic health records (EHRs) and healthcare information exchange (HIE) solutions is propelling the demand for Healthcare IT Integration products and services. Interface engines and integration software play a pivotal role in connecting disparate systems within healthcare organizations, enabling seamless data exchange and interoperability.

Moreover, the emergence of advanced technologies such as artificial intelligence (AI), machine learning (ML), and blockchain in healthcare is further driving the need for robust IT integration solutions. These technologies require seamless integration with existing healthcare IT infrastructure to harness their full potential in improving patient outcomes and optimizing healthcare processes.

As healthcare providers continue to prioritize interoperability and data exchange to support value-based care initiatives and enhance patient engagement, the demand for Healthcare IT Integration solutions is expected to witness significant growth in the coming years.

[vivekavicky12]

Data Science Unveiled: A Journey Across Industries

In the intricate tapestry of modern industries, data science stands as the master weaver, threading insights, predictions, and optimizations. From healthcare to finance, e-commerce to education, the applications of data science are as diverse as the sectors it transforms. Choosing the  Top Data Science Institute can further accelerate your journey into this thriving industry. In this exploration, we'll embark on a journey to unravel the pervasive influence of data science across various domains, witnessing its transformative power and impact on decision-making in the digital age.

Healthcare: Pioneering Precision Medicine

In the healthcare sector, data science acts as a beacon of innovation. It plays a pivotal role in patient diagnosis, treatment optimization, and personalized medicine. By analyzing vast datasets, healthcare professionals can identify patterns, predict disease outcomes, and tailor treatments to individual patients. This not only enhances the efficiency of healthcare delivery but also contributes to groundbreaking advancements in medical research.

Finance: Navigating Risk and Detecting Fraud

The financial landscape is ripe for data science applications, particularly in risk management, fraud detection, and algorithmic trading. Data-driven models analyze market trends, assess risk exposure, and identify fraudulent activities in real-time. This not only safeguards financial institutions but also empowers them to make informed investment decisions, optimizing portfolios for better returns.

E-commerce: Crafting Personalized Experiences

In the bustling world of e-commerce, data science is the engine driving personalized experiences. Recommendation systems powered by data analysis understand user behavior, preferences, and purchase history. This results in tailored product suggestions, optimized pricing strategies, and a seamless shopping journey that boosts sales and enhances customer satisfaction.

Telecommunications: Enhancing Connectivity and Predicting Maintenance

Telecommunications companies leverage data science for network optimization, predictive maintenance, and customer churn analysis. By analyzing vast datasets, they can optimize network performance, predict potential issues, and proactively address concerns. This not only enhances the reliability of communication networks but also improves the overall customer experience.

Marketing: Precision in Targeting and Campaign Optimization

Marketers rely on data science for precision in targeting and campaign optimization. Customer segmentation, behavior analysis, and predictive modeling help marketers tailor their strategies for maximum impact. This ensures that marketing efforts are not only more effective but also cost-efficient, yielding higher returns on investment.

Education: Tailoring Learning Experiences

In the realm of education, data science is reshaping how students learn. Personalized learning experiences, performance analytics, and resource optimization are made possible through data analysis. By understanding student behavior and learning patterns, educators can tailor educational strategies to individual needs, fostering a more adaptive and effective learning environment.

Manufacturing: Predictive Maintenance and Quality Control

Manufacturing enterprises harness data science for predictive maintenance, quality control, and supply chain optimization. Analyzing data from sensors and production lines allows for predictive maintenance, minimizing downtime and reducing defects. This not only enhances operational efficiency but also contributes to cost savings. Choosing the best Data Science Courses in Chennai is a crucial step in acquiring the necessary expertise for a successful career in the evolving landscape of data science.

Energy: Sustainability and Operational Efficiency

Data science is a driving force in the energy sector, contributing to sustainability and operational efficiency. Predictive maintenance of equipment, analysis of energy consumption patterns, and optimization of energy production are facilitated through data-driven insights. This not only ensures reliable energy supply but also contributes to the global push for sustainable practices.

Transportation and Logistics: Optimizing Routes and Operations

In transportation and logistics, data science is instrumental in optimizing routes, predicting demand, and managing fleets efficiently. By analyzing data on traffic patterns, delivery times, and inventory levels, companies can optimize logistics operations, reduce costs, and improve overall service delivery.

Human Resources: Talent Acquisition and Workforce Planning

Human Resources (HR) departments utilize data science for talent acquisition, employee engagement analysis, and workforce planning. Analyzing data on employee performance, satisfaction, and recruitment processes enables HR professionals to make informed decisions, attract top talent, and optimize organizational performance.

Social Media: Enhancing User Engagement and Content Recommendation

Social media platforms leverage data science for enhancing user engagement and content recommendation. Algorithms analyze user interactions, preferences, and behaviors to recommend personalized content and improve overall user experience. This not only keeps users engaged but also enhances the platform's ability to deliver relevant content.

Government and Public Policy: Informed Decision-Making

In the realm of government and public policy, data science aids in informed decision-making. Analyzing data on various facets, including crime rates, resource allocation, and citizen services, enables governments to optimize policies for the welfare of the public. This data-driven approach enhances governance and contributes to more effective public services.

As we traverse the vast landscape of industries, it becomes evident that data science is not merely a tool but a transformative force that connects and elevates diverse sectors. Its ability to extract insights, predict outcomes, and optimize processes is reshaping the way businesses and institutions operate. In an era defined by data, data science stands as a thread weaving through the fabric of innovation, connecting industries and shaping the future of decision-making. As we continue to explore the frontiers of technology, the influence of data science is set to expand, leaving an indelible mark on the evolution of industries across the globe.

[stevecarell600]

Drone Package Delivery Market Are Estimated To Increase During Period 2029 USD 31,188.7 Million At Exhibiting a CAGR of 53.94%

The global drone package delivery market size is projected to reach USD 7,388.2 million by 2028, exhibiting a CAGR of 41.8% during the forecast period. Widespread deployment of drones to deliver medical and food supplies amid the COVID-19 pandemic is expected to aid the market make substantial gains, observes Fortune Business Insights™ in its report, titled “Drone Package Delivery Market Size, Share & Industry Analysis, By Type (Fixed Wing and Rotary Wing), By Package Size (Less Than 2 Kg, 2-5 Kg, and above 5 Kg), By End Use (Restaurant & Food Supply, E-commerce, Healthcare, Retail Logistics & Transportation and others), and Regional Forecast, 2020-2028”.

Get Sample PDF Brochure:

The report states that the market value stood at USD 642.4 million in 2019 and shares the following information:

Comprehensive depiction of the industry outlook and trends;

Detailed insights into the upcoming opportunities in the market;

Tangible analysis of the market drivers, restrains, and all possible segments; and

In-depth assessment of the regional and competitive dynamics impacting the market.

Driving Factor

Emergence of Drone Startups in Logistics to Augment Market Potential

The growing demand for enhancing the efficiency of logistics operations has triggered a sudden emergence of startups specializing in drone technologies to cater to these needs. For example, DroneScan, a South Africa-based startup, designs drones that transmits live data of scanned items in warehouses, making inventory management more efficient and upping the productivity quotient of workers. An Italy-based startup, Archon, provides autonomous robotic drone services to facilitate supervised as well as unsupervised inspection of warehousing and logistics operations. The drone startup culture is gathering momentum in developing countries as well. For example, in India, several startups have spawned in the past few years that are providing next-gen drone services. Aarav Unmanned Systems, for instance, was started in 2013 and is India’s first drone company to develop drone solutions for commercial applications in the public and private sectors. These developments are expected to power the drone package delivery market growth in the forthcoming years.

Regional Insights

North America to Top Other Regions Backed by Rising Preference for Drone Deliveries by Shoppers

North America is set to dominate the drone package delivery market share during the forecast period owing to the increasing inclination of online shoppers towards delivery of goods through unmanned aerial vehicles (UAVs). With a market size of USD 237.7 million in 2019, the region is likely to retain its leading position, which will be supported by the strong financial support to drone startups in the US and Canada.

In Europe, the market is anticipated to be driven by the growing presence of tech companies that are expanding their operations in the region through collaborations and partnerships. Asia Pacific is expected to create exciting opportunities for market players on account of the emerging trend of online purchasing of groceries in the large cities of India, China, and Indonesia.

Competitive Landscape

Supportive Regulations to Novel Ideas to Feed Competitive Ardor of Key Players

With the scope for innovation widening, key players in the market drone package deliveries are engaged in coming up with novel drone solutions, especially during the current coronavirus crisis. Supporting their efforts are regulatory bodies that are easing flying norms and rules to ensure timely delivery of essential supplies to people.

List of Key Companies Profiled in the Drone Package Delivery Market Report:

DroneScan (South Africa)

Cheetah Logistics Technology (US)

Flytrex (Israel)

Flirtey (US)

Matternet, Inc. (US)

Boeing (US)

Amazon Inc. (US)

Wing Aviation LLC (US)

Workhorse Group Inc. (US)

Drone Delivery Canada Corp. (Canada)

Zipline (US)

DHL International GmbH (Germany)

United Parcel Service of America, Inc. (US)

FedEx (US)

Industry Developments:

August 2020: Amazon secured clearance from the Federal Aviation Administration (FAA) to deploy its Prime Air delivery drone fleet to efficiently and securely deliver packages to customers. Amazon is now the third company to receive FAA approval to operate drones on a commercial scale after UPS and the Alphabet-owned company, Wing.

May 2020: Wing, a subsidiary of Google’s parent company Alphabet, announced that it has made thousands of drone deliveries in Australia during the pandemic. Launched in Canberra in 2019, the demand for Wing’s services rose by 500% between February and April 2020.

[hariganesh858]

Biopharmaceutical Tubing Market

Biopharmaceutical Tubing Market Size, Share, Trends: Saint-Gobain Performance Plastics Leads

Increasing Acceptance of Biopharmaceutical Manufacturing Single-Use Systems

Market Overview:

Rising at a CAGR of 7.8%, the worldwide Biopharmaceutical Tubing Market is expected to reach USD 7.2 billion by 2031 from USD 3.9 billion in 2022. Over the projection period, North America should lead the market. The growing biopharmaceutical sector and rising need for sophisticated drug delivery systems are driving notable increase in the market for biopharmaceutical tubing. The need for high-quality biopharmaceutical tubing is being driven by the increased frequency of chronic illnesses and expanding aging population, which also inspire the need for creative medical equipment and drug delivery systems. Furthermore improving the performance and adaptability of biopharmaceutical tubing are technical developments in materials science and production techniques, thus driving market expansion.

DOWNLOAD FREE SAMPLE

Market Trends:

Single-use solutions in manufacturing techniques are clearly taking the stage in the biopharmaceutical sector. The need for more flexibility, lower contamination risks, and better cost-effectiveness in biopharmaceutical manufacture fuels this movement. Reduced cleaning and validation needs, less capital investment, and quicker changeover between manufacturing batches are just a few of the benefits of single-use systems—including disposable tubing and components. Consequently, biopharmaceutical businesses are using single-use tubing solutions more and more in their production processes, which increases demand for specialized disposable tubing materials satisfying strict quality and regulatory criteria.

Market Segmentation:

Silicone tubing is highly sought-after in the biopharmaceutical tubing industry because to its exceptional properties and versatility. Silicone has exceptional biocompatibility, flexibility, and resistance to extreme temperatures, making it ideal for use in peristaltic pumps, drug delivery systems, and other critical biopharmaceutical operations. Its low extractables and leachables profile, combined with its ability to hold its own throughout sterilisation processes, increase its appeal within the industry even more.

Market Key Players:

The biopharmaceutical tubing market is highly competitive, with strong rivalry among important companies emphasizing on innovation, quality, and customizing possibilities. Key companies such as Saint-Gobain Performance Plastics, Nordson Corporation, Zeus Industrial Products, Inc., Freudenberg Medical, W. L. Gore & Associates, Inc., NewAge Industries, Inc., Teleflex Incorporated, Optinova, and Lubrizol Corporation dominate the market.

Contact Us:

Name: Hari Krishna

Email us: hari.krishna@aurorawaveintellects.com

Website: https://aurorawaveintellects.com/

[dailyanarchistposts]

Topics: health care, monopoly

In a recent article for Tikkun, Dr. Arnold Relman argued that the versions of health care reform currently proposed by “progressives” all primarily involve financing health care and expanding coverage to the uninsured rather than addressing the way current models of service delivery make it so expensive. Editing out all the pro forma tut-tutting of “private markets,” the substance that’s left is considerable:

What are those inflationary forces? . . . [M]ost important among them are the incentives in the payment and organization of medical care that cause physicians, hospitals and other medical care facilities to focus at least as much on income and profit as on meeting the needs of patients. . . . The incentives in such a system reward and stimulate the delivery of more services. That is why medical expenditures in the U.S. are so much higher than in any other country, and are rising more rapidly. . . . Physicians, who supply the services, control most of the decisions to use medical resources. . . . The economic incentives in the medical market are attracting the great majority of physicians into specialty practice, and these incentives, combined with the continued introduction of new and more expensive technology, are a major factor in causing inflation of medical expenditures. Physicians and ambulatory care and diagnostic facilities are largely paid on a piecework basis for each item of service provided.

As a health care worker, I have personally witnessed this kind of mutual log-rolling between specialists and the never-ending addition of tests to the bill without any explanation to the patient. The patient simply lies in bed and watches an endless parade of unknown doctors poking their heads in the door for a microsecond, along with an endless series of lab techs drawing body fluids for one test after another that’s “been ordered,” with no further explanation. The post-discharge avalanche of bills includes duns from two or three dozen doctors, most of whom the patient couldn’t pick out of a police lineup. It’s the same kind of quid pro quo that takes place in academia, with professors assigning each other’s (extremely expensive and copyrighted) texts and systematically citing each other’s works in order to game their stats in the Social Sciences Citation Index. (I was also a grad assistant once.) You might also consider Dilbert creator Scott Adams’s account of what happens when you pay programmers for the number of bugs they fix.

One solution to this particular problem is to have a one-to-one relationship between the patient and a general practitioner on retainer. That’s how the old “lodge practice” worked. (See David Beito’s “Lodge Doctors and the Poor,” The Freeman, May 1994).

But that’s illegal, you know. In New York City, John Muney recently introduced an updated version of lodge practice: the AMG Medical Group, which for a monthly premium of $79 and a flat office fee of $10 per visit provides a wide range of services (limited to what its own practitioners can perform in-house). But because AMG is a fixed-rate plan and doesn’t charge more for “unplanned procedures,” the New York Department of Insurance considers it an unlicensed insurance policy. Muney may agree, unwillingly, to a settlement arranged by his lawyer in which he charges more for unplanned procedures like treatment for a sudden ear infection. So the State is forcing a modern-day lodge practitioner to charge more, thereby keeping the medical and insurance cartels happy—all in the name of “protecting the public.” How’s that for irony?

Regarding expensive machinery, I wonder how much of the cost is embedded rent on patents or regulatorily mandated overhead. I’ll bet if you removed all the legal barriers that prevent a bunch of open-source hardware hackers from reverse-engineering a homebrew version of it, you could get an MRI machine with a twentyfold reduction in cost. I know that’s the case in an area I’m more familiar with: micromanufacturing technology. For example, the RepRap—a homebrew, open-source 3-D printer—costs roughly $500 in materials to make, compared to tens of thousands for proprietary commercial versions.

More generally, the system is racked by artificial scarcity, as editor Sheldon Richman observed in an interview a few months back. For example, licensing systems limit the number of practitioners and arbitrarily impose levels of educational overhead beyond the requirements of the procedures actually being performed.

Libertarians sometimes—and rightly—use “grocery insurance” as an analogy to explain medical price inflation: If there were such a thing as grocery insurance, with low deductibles, to provide third-party payments at the checkout register, people would be buying a lot more rib-eye and porterhouse steaks and a lot less hamburger.

The problem is we’ve got a regulatory system that outlaws hamburger and compels you to buy porterhouse if you’re going to buy anything at all. It’s a multiple-tier finance system with one tier of service. Dental hygienists can’t set up independent teeth-cleaning practices in most states, and nurse-practitioners are required to operate under a physician’s “supervision” (when he’s out golfing). No matter how simple and straightforward the procedure, you can’t hire someone who’s adequately trained just to perform the service you need; you’ve got to pay amortization on a full med school education and residency.

Drug patents have the same effect, increasing the cost per pill by up to 2,000 percent. They also have a perverse effect on drug development, diverting R&D money primarily into developing “me, too” drugs that tweak the formulas of drugs whose patents are about to expire just enough to allow repatenting. Drug-company propaganda about high R&D costs, as a justification for patents to recoup capital outlays, is highly misleading. A major part of the basic research for identifying therapeutic pathways is done in small biotech startups, or at taxpayer expense in university laboratories, and then bought up by big drug companies. The main expense of the drug companies is the FDA-imposed testing regimen—and most of that is not to test the version actually marketed, but to secure patent lockdown on other possible variants of the marketed version. In other words, gaming the patent system grossly inflates R&D spending.

The prescription medicine system, along with state licensing of pharmacists and Drug Enforcement Administration licensing of pharmacies, is another severe restraint on competition. At the local natural-foods cooperative I can buy foods in bulk, at a generic commodity price; even organic flour, sugar, and other items are usually cheaper than the name-brand conventional equivalent at the supermarket. Such food cooperatives have their origins in the food-buying clubs of the 1970s, which applied the principle of bulk purchasing. The pharmaceutical licensing system obviously prohibits such bulk purchasing (unless you can get a licensed pharmacist to cooperate).

I work with a nurse from a farming background who frequently buys veterinary-grade drugs to treat her family for common illnesses without paying either Big Pharma’s markup or the price of an office visit. Veterinary supply catalogs are also quite popular in the homesteading and survivalist movements, as I understand. Two years ago I had a bad case of poison ivy and made an expensive office visit to get a prescription for prednisone. The next year the poison ivy came back; I’d been weeding the same area on the edge of my garden and had exactly the same symptoms as before. But the doctor’s office refused to give me a new prescription without my first coming in for an office visit, at full price—for my own safety, of course. So I ordered prednisone from a foreign online pharmacy and got enough of the drug for half a dozen bouts of poison ivy—all for less money than that office visit would have cost me.

Of course people who resort to these kinds of measures are putting themselves at serious risk of harassment from law enforcement. But until 1914, as Sheldon Richman pointed out (“The Right to Self-Treatment,” Freedom Daily, January 1995), “adult citizens could enter a pharmacy and buy any drug they wished, from headache powders to opium.”

The main impetus to creating the licensing systems on which artificial scarcity depends came from the medical profession early in the twentieth century. As described by Richman:

Accreditation of medical schools regulated how many doctors would graduate each year. Licensing similarly metered the number of practitioners and prohibited competitors, such as nurses and paramedics, from performing services they were perfectly capable of performing. Finally, prescription laws guaranteed that people would have to see a doctor to obtain medicines they had previously been able to get on their own.

The medical licensing cartels were also the primary force behind the move to shut down lodge practice, mentioned above.

In the case of all these forms of artificial scarcity, the government creates a “honey pot” by making some forms of practice artificially lucrative. It’s only natural, under those circumstances, that health care business models gravitate to where the money is.

Health care is a classic example of what Ivan Illich, in Tools for Conviviality, called a “radical monopoly.” State-sponsored crowding out makes other, cheaper (but often more appropriate) forms of treatment less usable, and renders cheaper (but adequate) treatments artificially scarce. Artificially centralized, high-tech, and skill-intensive ways of doing things make it harder for ordinary people to translate their skills and knowledge into use-value. The State’s regulations put an artificial floor beneath overhead cost, so that there’s a markup of several hundred percent to do anything; decent, comfortable poverty becomes impossible.

A good analogy is subsidies to freeways and urban sprawl, which make our feet less usable and raise living expenses by enforcing artificial dependence on cars. Local building codes primarily reflect the influence of building contractors, so competition from low-cost unconventional techniques (T-slot and other modular designs, vernacular materials like bales and papercrete, and so on) is artificially locked out of the market. Charles Johnson described the way governments erect barriers to people meeting their own needs and make comfortable subsistence artificially costly, in the specific case of homelessness, in “Scratching By: How the Government Creates Poverty as We Know It” (The Freeman, December 2007).

The major proposals for health care “reform” that went before Congress would do little or nothing to address the institutional sources of high cost. As Jesse Walker argued at Reason.com, a 100 percent single-payer system, far from being a “radical” solution,

would still accept the institutional premises of the present medical system. Consider the typical American health care transaction. On one side of the exchange you’ll have one of an artificially limited number of providers, many of them concentrated in those enormous, faceless institutions called hospitals. On the other side, making the purchase, is not a patient but one of those enormous, faceless institutions called insurers. The insurers, some of which are actual arms of the government and some of which merely owe their customers to the government’s tax incentives and shape their coverage to fit the government’s mandates, are expected to pay all or a share of even routine medical expenses. The result is higher costs, less competition, less transparency, and, in general, a system where the consumer gets about as much autonomy and respect as the stethoscope. Radical reform would restore power to the patient. Instead, the issue on the table is whether the behemoths we answer to will be purely public or public-private partnerships. [“Obama is No Radical,” September 30, 2009]

I’m a strong advocate of cooperative models of health care finance, like the Ithaca Health Alliance (created by the same people, including Paul Glover, who created the Ithaca Hours local currency system), or the friendly societies and mutuals of the nineteenth century described by writers like Pyotr Kropotkin and E. P. Thompson. But far more important than reforming finance is reforming the way delivery of service is organized.

Consider the libertarian alternatives that might exist. A neighborhood cooperative clinic might keep a doctor of family medicine or a nurse practitioner on retainer, along the lines of the lodge-practice system. The doctor might have his med school debt and his malpractice premiums assumed by the clinic in return for accepting a reasonable upper middle-class salary.

As an alternative to arbitrarily inflated educational mandates, on the other hand, there might be many competing tiers of professional training depending on the patient’s needs and ability to pay. There might be a free-market equivalent of the Chinese “barefoot doctors.” Such practitioners might attend school for a year and learn enough to identify and treat common infectious diseases, simple traumas, and so on. For example, the “barefoot doctor” at the neighborhood cooperative clinic might listen to your chest, do a sputum culture, and give you a round of Zithro for your pneumonia; he might stitch up a laceration or set a simple fracture. His training would include recognizing cases that were clearly beyond his competence and calling in a doctor for backup when necessary. He might provide most services at the cooperative clinic, with several clinics keeping a common M.D. on retainer for more serious cases. He would be certified by a professional association or guild of his choice, chosen from among competing guilds based on its market reputation for enforcing high standards. (That’s how competing kosher certification bodies work today, without any government-defined standards). Such voluntary licensing bodies, unlike state licensing boards, would face competition—and hence, unlike state boards, would have a strong market incentive to police their memberships in order to maintain a reputation for quality.

The clinic would use generic medicines (of course, since that’s all that would exist in a free market). Since local juries or arbitration bodies would likely take a much more common-sense view of the standards for reasonable care, there would be far less pressure for expensive CYA testing and far lower malpractice premiums.

Basic care could be financed by monthly membership dues, with additional catastrophic-care insurance (cheap and with a high deductible) available to those who wanted it. The monthly dues might be as cheap as or even cheaper than Dr. Muney’s. It would be a no-frills, bare-bones system, true enough—but to the 40 million or so people who are currently uninsured, it would be a pretty damned good deal.